Nulibry and Yorvipath are typically used in pediatric or rare disease contexts, while Ingrezza sees broader use across adult populations managing mental health conditions. How These Treatments …

2 days ago · A Phase III trial of Neurocrine Biosciences’ valbenazine in dyskinetic cerebral palsy has missed its primary and key secondary endpoints. The study randomized children and adults with the …

What Are Nulibry, Yorvipath, and Ingrezza? These three medications serve different patient populations with specific conditions that require specialized treatment approaches. Nulibry (fosdenopterin) is the …

This guide explores essential information about Nulibry, Yorvipath, and Ingrezza treatment, three therapies used in managing rare and specific medical conditions. While each medicine targets …

3 days ago · Neurocrine's Ingrezza failed its phase 3 trial for dyskinetic cerebral palsy, missing key goals. Read more here.

May 29, 2025 · Ingrezza (valbenazine) is used to treat tardive dyskinesia (TD) and chorea associated with Huntington's disease. Ingrezza uses, side effects, doses, and more.

Dec 16, 2025 · The company's clinical portfolio includes a rich pipeline of early- to mid-stage muscarinic agonists and VMAT2 inhibitors for the treatment of neuropsychiatric indications, and CRF-based …

View the medication guide of INGREZZA® (valbenazine) capsules for TD. See PI, including Boxed Warning, and Med Guide.

INGREZZA ® (valbenazine) capsules and INGREZZA ® SPRINKLE (valbenazine) capsules are indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated …

Sep 5, 2025 · Easy-to-read patient tips for Ingrezza covering how it works, benefits, risks, and best practices.